Nanotechnology Now

Our NanoNews Digest Sponsors
Heifer International



Home > News > BASF Venture Capital invests in North American investment fund ARCH Venture Fund VII

December 12th, 2007

BASF Venture Capital invests in North American investment fund ARCH Venture Fund VII

Abstract:
BASF Venture Capital America Inc., Fremont, CA, has invested in ARCH Venture Fund VII - a venture capital fund managed by ARCH Venture Partners, Chicago, IL. ARCH invests at a very early stage in start-up companies from the material science, life science, as well as information technology and biotechnology sectors in North America. The majority of these start-ups have been spun off from universities or national research laboratories. The total volume of the ARCH fund will be roughly $400 million fund. BASF Venture Capital will invest $5 million. Other investors in the fund are primarily universities, pension funds and financial institutions.

"ARCH is one of the most-respected venture capital funds in the U.S., supported by an impressive management team. ARCH will complement our strategy of investing in innovative companies that are active in BASF Group's five growth clusters - energy management, raw material change, nanotechnology plant biotechnology and white (industrial) biotechnology," said Keith Gillard, Principal of BASF Venture Capital America.

Source:
chemie.de

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

VC/Funding/Angel financing/Loans/Leases/Crowdfunding

Graphene Flagship start-up Bedimensional closes a second €10 million investment round February 10th, 2023

180 Degree Capital Corp. Reports +14.2% Growth in Q1 2021, $10.60 Net Asset Value Per Share as of March 31, 2021, and Developments From Q2 2021 May 11th, 2021

180 Degree Capital Corp. Issues Second Open Letter to the Board and Shareholders of Enzo Biochem, Inc. March 26th, 2021

180 Degree Capital Corp. Reports +6.7% Growth in Q4 2020, $9.28 Net Asset Value per Share as of December 31, 2020, and Developments from Q1 2021 Including Expected Investment in a Planned SPAC Sponsor February 22nd, 2021

Announcements

Nanotechnology: Flexible biosensors with modular design November 8th, 2024

Exosomes: A potential biomarker and therapeutic target in diabetic cardiomyopathy November 8th, 2024

Turning up the signal November 8th, 2024

Nanofibrous metal oxide semiconductor for sensory face November 8th, 2024

NanoNews-Digest
The latest news from around the world, FREE




  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More











ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project